Danaher Co. (NYSE:DHR) Shares Acquired by Ballast Advisors LLC

Ballast Advisors LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 1.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,751 shares of the conglomerate’s stock after acquiring an additional 50 shares during the period. Ballast Advisors LLC’s holdings in Danaher were worth $1,043,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after buying an additional 4,163,657 shares in the last quarter. Legal & General Group Plc lifted its position in Danaher by 2.4% in the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after purchasing an additional 139,989 shares during the period. Capital Research Global Investors increased its position in shares of Danaher by 1.0% during the 1st quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate’s stock valued at $1,279,932,000 after purchasing an additional 52,679 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Danaher by 2.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock valued at $849,195,000 after buying an additional 85,081 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its holdings in Danaher by 22.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after acquiring an additional 563,546 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DHR has been the topic of several recent research reports. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Leerink Partners increased their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Stifel Nicolaus lifted their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Bank of America upped their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company initiated coverage on shares of Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $287.16.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.90% of the stock is owned by company insiders.

Danaher Price Performance

Shares of NYSE:DHR opened at $248.66 on Wednesday. The business has a fifty day simple moving average of $266.16 and a 200 day simple moving average of $260.84. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 1 year low of $192.35 and a 1 year high of $281.70. The firm has a market cap of $179.60 billion, a price-to-earnings ratio of 47.74, a P/E/G ratio of 4.55 and a beta of 0.85.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.02 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.51 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio is currently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.